Cape Town - 2026 ISMRM-ISMRT Annual Meeting and Exhibition
9 May 2026 – 14 May 2026 · Cape Town, South Africa
466-01-001 ISMRM Abstract

MRI-Based Risk Stratification of Immunotherapy Response in Locally Advanced Rectal Cancer: A Pilot Study

Primary: Acquisition & Reconstruction - Image Reconstruction: Non-AI
Secondary: Body - Pelvis
466-01-001 · Rectal Cancer · Tuesday, 12 May, 8:20 AM–9:15 AM · Digital Posters Row G
Keywords: MRI Risk Stratification Locally advanced rectal cancer Neoadjuvant immunochemotherapy (NICT) Therapeutic response
Accepted
Jiali Zhang 1, Pu-Yeh Wu2,3,4, Cong Sun1
1Department of Radiograpy, Shandong Provincial Hospital Affiliated to Shandong First Medical University (Shandong Provincial Hospital), Jinan, China
2GE Healthcare, Beijing, China
3GE Healthcare, Beijing, China
4GE Healthcare, Taipei, Taiwan, Taiwan
Presenting Author: Jiali Zhang

Synopsis

Motivation:
Goals:
Approach:
Results:
Full abstract & presentation

The full text, figures, and any recorded presentation for this abstract are not shown here. Log in if you are a member or registered attendee with access.

Full abstracts, figures, and presentations for Cape Town - 2026 ISMRM-ISMRT Annual Meeting and Exhibition are available to registered attendees. This content becomes freely available to the public roughly two years after the meeting.

To request or purchase access, contact the ISMRM Central Office at info@ismrm.org.

Log in

References

1. Siegel RL et al. Colorectal cancer statistics, 2023. CA Cancer J Clin, 2023. doi: 10.3322/caac.21772 [doi]
2. Long-term outcome in patients with a pathological Maas M et al. Long-term outcome in patients with a pathological complete response after chemoradiation for rectal cancer: a pooled analysis of individual patient data. Lancet Oncol, 2010. doi: 10.1016/S1470-2045(10)70172-8 [doi]
3. Kalbasi A et al. Radiation and immunotherapy: a synergistic combination. J Clin Invest, 2013. doi: 10.1172/JCI69219 [doi]
4. Lin Z et al. Phase II, single-arm trial of preoperative short-course radiotherapy followed by chemotherapy and camrelizumab in locally advanced rectal cancer. J ImmunoTher Cancer, 2021. doi: 10.1136/jitc-2021-003554 [doi]
5. Xia F et al. Randomized phase II trial of immunotherapy-based total neoadjuvant therapy for proficient mismatch repair or microsatellite stable locally advanced rectal cancer (TORCH). J Clin Oncol, 2024. doi: 10.1200/JCO.23.02261 [doi]
6. Tian F et al. Total neoadjuvant treatment with short-course radiotherapy followed by sintilimab plus capecitabine-oxaliplatin versus short-course radiotherapy followed by capecitabine-oxaliplatin in patients with locally advanced rectal cancer (SPRING-01): a single-centre, open-label, phase 2, randomised controlled trial. Lancet Oncol, 2025. doi: 10.1016/S1470-2045(25)00286-4 [doi]
7. Lord AC et al. Assessment of the 2020 NICE criteria for preoperative radiotherapy in patients with rectal cancer treated by surgery alone in comparison with proven MRI prognostic factors: a retrospective cohort study. Lancet Oncol, 2022. doi: 10.1016/S1470-2045(22)00214-5 [doi]
8. Smith NJ et al. Prognostic significance of magnetic resonance imaging-detected extramural vascular invasion in rectal cancer. Br J Surg, 2008. doi: 10.1002/bjs.5917 [doi]
9. Zhao M et al. An MRI-based scoring system for pretreatment risk stratification in locally advanced rectal cancer. Br J Cancer, 2023. doi: 10.1038/s41416-023-02384-x [doi]
10. Sonal S et al. Molecular basis of extramural vascular invasion (EMVI) in colorectal carcinoma. Ann Surg Oncol, 2022. doi: 10.1245/s10434-022-12212-w [doi]

Cite this abstract

http://echo.ismrm.org/p/ISMRM2026/466-01-001